Using advanced imaging to predict outcomes in early-stage triple negative breast cancer
Label-Free Optical Redox Imaging for Pretreatment Prognosis of Early-Stage Triple Negative Breast Cancer
This study is exploring a new imaging technique that looks at the unique metabolism of early-stage triple negative breast cancer tumors to help doctors understand how the cancer might behave and create personalized treatment plans for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10931683 on NIH RePORTER |
What this research studies
This research investigates the use of Label-Free Optical Redox Imaging (ORI) to assess the metabolic characteristics of early-stage triple negative breast cancer (TNBC) tumors. By analyzing the intrinsic fluorescence signals of specific molecules within the tumor, the study aims to identify different metabolic subtypes that may influence disease progression. This innovative imaging technique offers a high-resolution, three-dimensional view of the tumor's microenvironment, potentially providing more accurate prognostic information than traditional methods. Patients with TNBC may benefit from this approach by receiving tailored treatment plans based on their tumor's unique metabolic profile.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early-stage triple negative breast cancer who have not yet received treatment.
Not a fit: Patients with non-triple negative breast cancer or those who have already undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment strategies for patients with early-stage triple negative breast cancer, improving their chances of favorable outcomes.
How similar studies have performed: Preliminary results from earlier studies using similar imaging techniques have shown promise in predicting disease progression, suggesting that this approach may be effective.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Li, Lin Z — University of Pennsylvania
- Study coordinator: Li, Lin Z
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.